Polyethylene glycol and prevalence of colorectal adenomas: Population-based study of 1165 patients undergoing colonoscopy

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 10, 2006, Pages 1196-1199

  Dorval, Etienne ^a   Jankowski, Jean Marie ^b   Barbieux, Jean Pierre ^a   Viguier, Jérôme ^a   Bertrand, Philippe ^a   Brondin, Brigitte ^a   Bougnoux, Philippe ^a   Corpet, Denis E ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b Cabinet Medical   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IDROCOL; LAXATIVE; MACROGOL; MACROGOL 3350; MACROGOL 4000; NONSTEROID ANTIINFLAMMATORY AGENT; POLOXAMER;

ADULT; AGED; ARTICLE; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL TUMOR; CONSTIPATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE;

ADENOMA; ADULT; AGE FACTORS; AGED; CATHARTICS; COLONOSCOPY; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYETHYLENE GLYCOLS; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 33750594082     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(06)73511-4     Document Type: Article

References (34)

1. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340:101-7.
2. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-9.
3. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
4. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
5. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36.
6. Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 2003;157:661-4.
7. Chaussade S, Minic M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther 2003;17:165-72.
8. Loening-Baucke V.Polyethylene glycol without electrolytes for children with constipation and encopresis. J Pediatr Gastroenterol Nutr 2002;34:372-7.
9. Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J 2001;94:478-81.
10. Corazziari E, Badiali D, Bazzocchi G, Bassotti G, Roselli P, Mastropaolo G, et al. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000;46:522-6.
11. DiPalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000;95:446-50.
12. Attar A, Lemann M, Ferguson A, Halphen M, Boutron MC, Flourie B, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999;44:226-30.
13. Corazziari E, Badiali D, Habib FI, Reboa G, Pitto G, Mazzacca G, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996;41:1636-42.
14. Couturier D. Comparative study of Forlax and Transipeg in the treatment of functional constipation in the adult. Ann Gastroenterol Hepatol (Paris) 1996;32:135-40.
15. Corpet DE, Parnaud G. Polyethylene-glycol, a potent suppressor of azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 1999;20:915-8.
16. Corpet DE, Parnaud G, Delverdier M, Peiffer G, Tache S. Consistent and fast inhibition of colon carcinogenesis by polyethylene glycol in mice and rats given various carcinogens. Cancer Res 2000;60:3160-4.
17. Parnaud G, Tache S, Peiffer G, Corpet DE. Polyethylene-glycol suppresses colon cancer and causes dose-dependent regression of azoxymethane-induced aberrant crypt foci in rats. Cancer Res 1999;59:5143-7.
18. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002;43:1-21.
19. Parnaud G, Tache S, Peiffer G, Corpet DE. Pluronic F68 block polymer, a very potent suppressor of carcinogenesis in the colon of rats and mice. Br J Cancer 2001;84:90-3.
20. Roy HK, Gulizia J, DiBaise JK, Karolski WJ, Ansari S, Madugula M, et al. Polyethylene glycol inhibits intestinal neoplasia and induces epithelial apoptosis in Apc(min) mice. Cancer Lett 2004;215:35-42.
21. Naigamwalla D, Chia MC, Tran TT, Medline A, Hay K, Gallinger S, et al. Polyethylene glycol 8000 and colon carcinogenesis: inhibition in the F344 rat, promotion in the Min mouse. Cancer Res 2000;60:6856-8.
22. Parnaud G, Corpet DE, Gamet-Payrastre L. Cytostatic effect of polyethylene glycol on human colonic adenocarcinoma cells. Int J Cancer 2001;92:63-9.
23. Roy HK, DiBaise JK, Black J, Karolski WJ, Ratashak A, Ansari S. Polyethylene glycol induces apoptosis in HT-29 cells: potential mechanism for chemoprevention of colon cancer. FEBS Lett 2001;496:143-6.
24. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
25. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955-60.
26. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9.
27. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 2003;125:404-12.
28. Bruce WR. Counterpoint: from animal models to prevention of colon cancer. Cancer Epidemiology Biomarkers & Prevention 2003;12:400-403.
29. Taché S, Parnaud G, Van Beek E, Corpet DE. Polyethylene glycol, unique among laxatives, suppresses aberrant crypt foci, by elimination of cells. Scand J Gastroenterol 2006 (in press).
30. McCashland TM, Brand R, Lyden E, de Garmo P. Gender differences in colorectal polyps and tumors. Am J Gastroenterol 2001;96:882-6.
31. Frexinos J, Denis P, Allemand H, Allouche S, Los F, Bonnelye G. Etude descriptive des symptômes fonctionnels digestifs dans la population générale française. Gastroenterol Clin Biol 1998;22:785-91.
32. Bommelaer G, Dorval E, Denis P, Czernichow P, Frexinos J, Pelc A, et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol Clin Biol 2002;26:1118-23.
33. Jacobs EJ, White E. Constipation, laxative use, and colon cancer among middle-aged adults. Epidemiology 1998;9:385-91.
34. Roberts MC, Millikan RC, Galanko JA, Martin C, Sandler RS. Constipation, laxative use, and colon cancer in a North Carolina population. Am J Gastroenterol 2003;98:857-64.